HRP20200444T1 - U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba - Google Patents

U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba Download PDF

Info

Publication number
HRP20200444T1
HRP20200444T1 HRP20200444TT HRP20200444T HRP20200444T1 HR P20200444 T1 HRP20200444 T1 HR P20200444T1 HR P20200444T T HRP20200444T T HR P20200444TT HR P20200444 T HRP20200444 T HR P20200444T HR P20200444 T1 HRP20200444 T1 HR P20200444T1
Authority
HR
Croatia
Prior art keywords
compound
acid
aqueous
patient
preparation
Prior art date
Application number
HRP20200444TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin P. Maguire
Original Assignee
Milestone Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57125495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20200444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Milestone Pharmaceuticals Inc. filed Critical Milestone Pharmaceuticals Inc.
Publication of HRP20200444T1 publication Critical patent/HRP20200444T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20200444TT 2015-04-14 2016-04-13 U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba HRP20200444T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147427P 2015-04-14 2015-04-14
EP16779363.7A EP3283067B1 (de) 2015-04-14 2016-04-13 Stark wasserlösliche salze eines kurz wirkenden phenylalkylamin-kalziumkanalblockers und verwendungen davon
PCT/CA2016/050425 WO2016165014A1 (en) 2015-04-14 2016-04-13 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof

Publications (1)

Publication Number Publication Date
HRP20200444T1 true HRP20200444T1 (hr) 2020-06-12

Family

ID=57125495

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200444TT HRP20200444T1 (hr) 2015-04-14 2016-04-13 U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba

Country Status (28)

Country Link
US (13) US10117848B2 (de)
EP (3) EP4428119A3 (de)
JP (1) JP6785792B2 (de)
KR (3) KR20250057109A (de)
CN (2) CN113694019A (de)
AU (1) AU2016249030B2 (de)
BR (1) BR112017021620B1 (de)
CA (2) CA2982622C (de)
CY (1) CY1122931T1 (de)
DK (1) DK3283067T3 (de)
ES (2) ES2778673T3 (de)
HR (1) HRP20200444T1 (de)
HU (1) HUE049570T2 (de)
IL (1) IL254889B (de)
LT (1) LT3283067T (de)
MA (2) MA46679B1 (de)
MD (1) MD3283067T2 (de)
ME (1) ME03679B (de)
MX (1) MX372659B (de)
PL (2) PL3283067T3 (de)
PT (2) PT3689344T (de)
RS (1) RS60154B1 (de)
RU (1) RU2731918C2 (de)
SI (1) SI3283067T1 (de)
SM (1) SMT202000149T1 (de)
UA (1) UA121330C2 (de)
WO (1) WO2016165014A1 (de)
ZA (2) ZA201706648B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4119137A1 (de) 2021-07-15 2023-01-18 Milestone Pharmaceuticals Inc. Verabreichungsmethoden für stark wasserlösliche salze eines kurzwirkenden phenylalkylamin-calciumkanalblockers
KR20240147942A (ko) 2023-03-31 2024-10-10 주식회사 엘지화학 오토택신 저해제로서의 신규한 벤즈이미다졸론 유도체 화합물
WO2025215083A1 (en) 2024-04-10 2025-10-16 Dipharma Francis S.R.L. Method for preparing a drug used for paroxysmal supraventricular tachycardia
WO2025229679A1 (en) * 2024-04-30 2025-11-06 Cipla Limited Process for synthesis of etripamil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605074D0 (en) * 1996-03-11 1996-05-08 Chiroscience Ltd Dosage forms and uses
CA2446904A1 (en) * 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US6831663B2 (en) * 2001-05-24 2004-12-14 Microsoft Corporation System and process for automatically explaining probabilistic predictions
US20050191245A1 (en) 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders
WO2008019106A1 (en) * 2006-08-04 2008-02-14 Artesian Therapeutics, Inc. Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor
CA2693627C (en) 2007-06-20 2016-01-12 Milestone Pharmaceuticals Inc. Short acting phenylalkylamine calcium channel blockers and uses thereof
US20090318413A1 (en) 2008-06-18 2009-12-24 Universite Victor Segalen Bordeaux 2 Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Also Published As

Publication number Publication date
IL254889B (en) 2021-07-29
ME03679B (de) 2020-10-20
ES2986137T3 (es) 2024-11-08
US20230414553A1 (en) 2023-12-28
US20250332137A1 (en) 2025-10-30
CY1122931T1 (el) 2021-10-29
EP3283067A4 (de) 2018-12-05
RU2017134553A (ru) 2019-04-05
AU2016249030B2 (en) 2020-08-27
US20230157990A1 (en) 2023-05-25
ES2778673T3 (es) 2020-08-11
KR20250057109A (ko) 2025-04-28
KR20180019508A (ko) 2018-02-26
BR112017021620A2 (pt) 2018-07-03
EP3283067A1 (de) 2018-02-21
CA2982622A1 (en) 2016-10-20
CA3203288A1 (en) 2016-10-20
US20190022048A1 (en) 2019-01-24
US20220040139A1 (en) 2022-02-10
KR102653347B1 (ko) 2024-04-02
NZ736249A (en) 2024-07-05
HUE049570T2 (hu) 2020-10-28
US20200368195A1 (en) 2020-11-26
UA121330C2 (uk) 2020-05-12
US20200121631A1 (en) 2020-04-23
ZA201807495B (en) 2024-04-24
MA46679A (fr) 2018-02-21
CN107613970B (zh) 2021-10-19
PL3689344T3 (pl) 2024-11-04
US20210205258A1 (en) 2021-07-08
HK1249417A1 (en) 2018-11-02
MA52480A (fr) 2022-03-09
KR20240044546A (ko) 2024-04-04
JP6785792B2 (ja) 2020-11-18
SMT202000149T1 (it) 2020-05-08
WO2016165014A1 (en) 2016-10-20
US20250090488A1 (en) 2025-03-20
PT3283067T (pt) 2020-03-31
MX372659B (es) 2020-03-26
LT3283067T (lt) 2020-06-25
EP3283067B1 (de) 2020-01-01
MX2017013355A (es) 2019-01-21
US10117848B2 (en) 2018-11-06
US20240277652A1 (en) 2024-08-22
EP3689344B1 (de) 2024-06-05
DK3283067T3 (da) 2020-03-30
SI3283067T1 (sl) 2020-07-31
IL254889A0 (en) 2017-12-31
JP2018514527A (ja) 2018-06-07
ZA201706648B (en) 2020-01-29
AU2016249030A1 (en) 2017-10-26
MA46679B1 (fr) 2020-04-30
RU2017134553A3 (de) 2019-11-13
CN113694019A (zh) 2021-11-26
MD3283067T2 (ro) 2020-05-31
PL3283067T3 (pl) 2020-09-21
US20190269643A1 (en) 2019-09-05
EP3689344A1 (de) 2020-08-05
RU2731918C2 (ru) 2020-09-09
CN107613970A (zh) 2018-01-19
CA2982622C (en) 2023-08-22
EP4428119A3 (de) 2024-11-13
US20180110752A1 (en) 2018-04-26
RS60154B1 (sr) 2020-05-29
PT3689344T (pt) 2024-09-04
EP4428119A2 (de) 2024-09-11
US20220296556A1 (en) 2022-09-22
BR112017021620B1 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
CN101588789B (zh) 用于治疗牛和其它动物炎症的药物组合物和方法
HRP20200444T1 (hr) U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba
CN105748408A (zh) 微乳、微乳制剂及其制备方法
BRPI0508933A (pt) composições para entrega tópica
JP2019501861A5 (de)
JP2015523361A5 (ja) 低分子薬の非経口注射用の安定な製剤
TWI813571B (zh) 防沉澱的小分子藥調配物
CN105246471A (zh) 外用药物组合物
JP2017533972A5 (de)
CN103054793B (zh) 一种用于治疗婴幼儿血管瘤的盐酸普萘洛尔乳膏及其制备方法
US20200301526A1 (en) Novel non-aqueous topical solution of diclofenac and process for preparing the same
HRP20200329T1 (hr) Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije
FI3551166T3 (fi) Topikaalinen fenytoiini perifeerisen neuropaattisen kivun hoitoon
JP2016517882A5 (de)
AU2015237371A1 (en) Stable veterinary anthelmintic formulations
JP2018514527A5 (de)
CN101125145A (zh) 局部用前列腺素微乳剂及其制备方法
RU2017132449A (ru) Фармацевтические композиции ингибитора c1-эстеразы
US20240123043A1 (en) Pharmaceutical compositions comprising ranpirnase
ES2608339T3 (es) Emulsión antitumoral a base de Lipiodol para el tratamiento del cáncer
US10682337B2 (en) Compositions and methods for treatment and prevention of pyrexia in horses
US20140107130A1 (en) Oral Solution Formulations of Aripiprazole
EP2514409A1 (de) Topische pharmazeutische Zusammensetzungen aus Nimesulid und Methylsuflonylmethan
JP7331149B2 (ja) 直腸および局所投与のためのゲル
NZ736249B2 (en) Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof